Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.16 USD | +2.02% | -12.26% | -52.00% |
10/05 | UBS Cuts Price Target on ACADIA Pharmaceuticals to $25 From $27, Keeps Buy Rating | MT |
10/05 | Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-52.00% | 245.52Cr | |
+26.23% | 4.92TCr | |
+0.57% | 4.21TCr | |
+50.24% | 4.04TCr | |
-5.26% | 2.89TCr | |
+12.34% | 2.61TCr | |
-21.90% | 1.87TCr | |
+8.51% | 1.33TCr | |
+31.14% | 1.23TCr | |
-0.21% | 1.2TCr |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- Transcript : ACADIA Pharmaceuticals Inc., Q1 2023 Earnings Call, May 08, 2023